Easywell Biomedicals, Inc.
1799.TWO
Taipei Exchange33.45
TWD
+0.15
- -
Easywell Biomedicals, Inc.
1799.TWO
(Taipei Exchange)
Recent
price
33.45
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Easywell Biomedicals, Inc. (1799.TWO) develops, manufactures and sells active pharmaceutical ingredients, over-the-counter drug products, medical devices and regenerative medicine therapies. The company offers digital clinical thermometers; infrared ear thermometers and non-contact forehead thermometers; transcutaneous electrical nerve stimulation (TENS) products for pain relief; in vitro diagnostic devices including meters and test strips; pharmaceuticals encompassing technically challenging generics and 505(b)(2) products such as anti-cough medicine TLX-001, anti-urinary incontinence medicine TLX-005, breast cancer treatment TLX-006 for PMS women, anti-depressants TLX-007 and TLX-004, Parkinson patch TWB-201, urinary medicine TLX-501, pneumonia medicine TLX-502, postpartum hemorrhage treatments TLX-015 and TLX-018, liquid oral epilepsy drug ET-101, sacubitril-valsartan sodium tablets HH-001 (Yuexintuo), neurological disorder treatment TLX-050 and injectable TLX-054; health foods; and regenerative therapies like fetal skin cell product TWB-103 for wound healing. Easywell Biomedicals operates through Drug Development and Other segments, with facilities including a cGMP medical device plant in Shenzhen, China, a cGMP pharmaceutical development and manufacturing site in Cranbury, New Jersey, USA via subsidiary Tulex Pharmaceuticals Inc., and headquarters in Hsinchu Science Park, Taiwan; it serves markets in America, Europe, China and Asia. Incorporated in 1998 as Actherm Inc. and renamed Easywell Biomedicals in July 2015, the company expanded via acquisition of Magnifica Inc. in 2014 for pharmaceutical capabilities and Transwell Biotech Inc. in 2016 for regenerative medicine. Recent developments include a December 2024 collaboration with partners on TLX-050 neurological drug adding a third-party ally; September 2024 update on HH-001 China market expansion; March 2024 launch of subsidiary Jiangsu Huahan's HH-001 sacubitril-valsartan by grandson company; October 2023 NMPA approval for HH-001; May 2023 US FDA Phase II clearance for TLX-032; March 2023 exclusive licensing and CDMO deal with Eton Pharmaceuticals for pediatric rare disease drug; strategic partnership with Formosa Laboratories for TLX-054 injectable; and a collaborative development agreement with Handa Pharmaceuticals and Handa Neuroscience for TLX-050.